Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
30 December 2018 Senior executives increase their holdings in Scandion Oncology Download Presentation Webcast Workbook
21 December 2018Regulatory Senior executives increase their holdings in Scandion Oncology A/S Download Presentation Webcast Workbook
14 December 2018Regulatory Scandion Oncology informs on the selection of collaborator for the Boost4Health Internationalisation grant Download Presentation Webcast Workbook
22 November 2018Regulatory Scandion Oncology – Interim Report Q3 2018 Download Presentation Webcast Workbook
13 November 2018Regulatory Scandion Oncology to receive EU support to boost international development Download Presentation Webcast Workbook
4 October 2018Regulatory The subscription period for Scandion Oncology A/S new share issue begins today Download Presentation Webcast Workbook
1 October 2018Regulatory Scandion Oncology A/S approved for listing at Spotlight Stock Market Download Presentation Webcast Workbook
10 September 2018 Presentation at the 13th Annual EORTC PatoBiology Group Meeting on September 15, 2018 in Hamburg, Germany Download Presentation Webcast Workbook
10 September 2018 Presentation at the conference “Response and Resistance in Cancer therapy” on September 10, 2018 in Kent, UK Download Presentation Webcast Workbook
10 September 2018 Scandion has submitted a patent application regarding a novel mechanism of action for its lead compound SCO-101 Download Presentation Webcast Workbook
5 September 2018 Scandion Oncology A/S presents at the MVA Oncology Network Pitch event at Medicon Village, Lund, Sweden, September 5th, 2018 Download Presentation Webcast Workbook
16 August 2018 Thomas Feldthus has joined the Board of Scandion Oncology Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.